Corticosteroid-induced diabetes in patients with chronic obstructive pulmonary disease: Brief review

Clinical Pulmonary Medicine

Volumn 15, Issue 3, 2008, Pages 127-131

  Tryfon, Stavros ^a   Papanas, Nikolaos ^b  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Chronic obstructive pulmonary disease; Corticoids; Diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; GLUCOCORTICOID; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METHYLPREDNISOLONE; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PREDNISONE; REPAGLINIDE; SULFONYLUREA; VOGLIBOSE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFECT; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RANDOMIZATION; REVIEW; RISK BENEFIT ANALYSIS;

EID: 44649116741     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/CPM.0b013e318170f82e     Document Type: Review

References (56)

1. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest. 1997;111:732-743.
2. Saymer A, Aytemur ZA, Cirit M. Systemic glucocorticoids in severe exacerbations of COPD. Chest. 2001;119:726-730.
3. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators. Am J Resp Crit Care Med. 1996;154:959-967 [Erratum: Am J Resp Crit Care Med. 1997;155:386].
4. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999;340:1941-1947.
5. Pauwels RA, Buist SA, Calverley PMA, et al. On behalf of the GOLD Scientific Committee. Global strategy for diagnosis and management and prevention of COPD. Am J Resp Crit Care Med. 2001;163:1256-1276.
6. Medical Advisory Panel for the Pharmacy Benefits Management Strategic Healthcare Group. The pharmacologic management of chronic obstructive pulmonary disease. Veterans Health Administration, Publication 02-0012, 2002.
7. Grunfeld C, Baird K, van Obberghen E, et al. Glucocorticoid-induced insulin resistance in vitro: evidence for both receptor and postreceptor defects. Endocrinology. 1981;109:1723-1730.
8. Willi SM, Kennedy A, Wallace P, et al. Troglitazone antagonizes metabolic effects of glucocorticoids in humans. Diabetes. 2002;51:2895-2902.
9. Simonson GD, Kendall DM. Diagnosis of insulin resistance and associated syndromes: the spectrum from the metabolic syndrome to type 2 diabetes mellitus. Coron Artery Dis. 2005;16:465-472.
10. McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev. 1988;4:17-30.
11. Dirlewanger M, Schneiter PH, Paquot N, et al. Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr. 2000;19:29-34.
12. Kraus-Friedmann N. Hormonal regulation of hepatic gluconeogenesis. Physiol Rev. 1984;64:170-259.
13. Boyle PJ. Cushing's disease, glucocorticoid excess, glucocorticoid deficiency and diabetes. Diabetes Rev. 1993;1:301-311.
14. Pagano G, Cavallo-Perin P, Cassader M, et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest. 1983;72:1814-1820.
15. Dimitriadis G, Leighton B, Parry-Billings M, et al. Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J. 1997;321:707-712.
16. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab. 1982;54:131-138.
17. Fantus IG, Ryan J, Hizuka N, et al. The effect of glucocorticoids on the insulin receptor: an in vivo and in vitro study. J Clin Endocrinol Metab. 1981;52:953-960.
18. Wantanabe N, Kobayashi M, Maegawa H, et al. In vitro effects of glucocorticoid on glucose transport in rat adipocytes: evidence for a post-receptor coupling defect in insulin action. J Biochem. 1984;96:1893-1902.
19. Delaunay F, Khan A, Cintra A, et al. Pancreatic â cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest. 1997;100:2094 -2098.
20. Lambillotte C, Gilon P, Henquin J-C. Direct glucocorticoid inhibition of insulin secretion. J Clin Invest. 1997;99:414-423.
21. Gremlich S, Roduit R, Thorens B. Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic â cells. J Biol Chem. 1997;272:3216-3222.
22. Ward WK, LaCava EC, Paquette TL, et al. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin dependent) diabetes mellitus and experimental insulin resistance. Diabetologia. 1987;30:698-702.
23. Kahn SE, Horber FF, Prigeon RL, et al. Effect of glucocorticoid and growth hormone treatment on proinsulin levels in humans. Diabetes. 1993;42:1082-1085.
24. Bruno A, Cavallo-Perin P, Cassader M, et al. Deflazacort vs. prednisone: effect on blood glucose control in insulin-treated diabetics. Arch Intern Med. 1987;147:679-680.
25. Hirsch IB, Paauw DS. Diabetes management in special situations. Endocrinol Meatb Clin North Am. 1997;26:631-645.
26. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycemia in patients with rheumatoid arthritis on corticosteroid therapy. SMJ. 2004;49:139-141.
27. Greenstone MA, Shaw AB. Alternate day corticosteroid causes alternate day hyperglycemia. Postgrad Med J. 1987;63:761-764.
28. Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation. 1991;51:374-377.
29. Agarwal DK, Jeloka T, Sharma AP, et al. Steroid induced diabetes mellitus presenting as diabetic ketoacidosis. Indian J Nephrol. 2002;12:122-123.
30. Arner P, Gunnarsson R, Blomdahl S, et al. Some characteristics of steroid diabetes: A study in renal-transplant patients receiving high-dose corticosteroid therapy. Diabetes Care. 1983;6:23-25.
31. Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycaemic therapy. Arch Intern Med. 1994;154:97-101.
32. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-induced diabetes mellitus. Rheum Dis Clin North Am. 1999;25:489-505.
33. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Inten Med. 1994;236:619-632.
34. Smyllie HC, Connolly CK. Incidence of serious complications of corticosteroid therapy in respiratory disease. A retrospective survey of patients in the Brompton Hospital. Thorax. 1968;23:571-581.
35. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354:456-460.
36. Rodrigues J, Niederman MS, Fein AM, et al. Nonresolving pneumonia in steroid-treated patients with obstructive pulmonary disease. Am J Med. 1992;93:29-34.
37. Tryfon S, Saroglou M, Dramba V, et al. Hyperglycemia and its association with outcomes in people admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. (Oral presentation) ERJ 2006 Munich, Germany.
38. Baker EH, Janaway CH, Philips BJ, et al. Hyperglycemia is associated with poor outcomes in people admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61:284-289.
39. Wachtel TJ, Silliman RA, Lamberton P. Predisposing factors for the diabetic hyperosmolar state. Arch Intern Med. 1987;147:499 -501.
40. American Diabetes Association Task Force for writing nutrition principles and recommendations for the management of diabetes and related complications. American Diabetes Association position statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. J Am Diet Assoc. 2002;102:109-118.
41. American Diabetes Association. Physical activity/Exercise and diabetes mellitus. Diabetes Care. 2003;26(Suppl 1):S73-S77.
42. Agustí AGN, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347-360.
43. Rakovac I, Jeitler K, Gfrerer RJ, et al; and the FQSD Austria. Patients with type 2 diabetes treated with metformin: prevalence of contraindications and their correlation with discontinuation. Diabet Med. 2005;22:662-664.
44. Fantus G. Metformin's contraindications: need for know. CMAJ. 2005;173:505-507.
45. Fujibayashi K, Nagasaka S, Itabashi N, et al. Troglitazone efficacy in a subject with glucocorticoid-induced diabetes. Diabetes Care. 1999;22:2088-2089.
46. Okumura S, Takeda N, Takami K, et al. Effects of troglitazone on dexamethasone-induced insulin resistance in rats. Metabolism. 1998;47:351-354.
47. Willi SM, Kennedy A, Brant BP, et al. Effective use of thiazolidinediones for the treatment of glucocortcoid-induced diabetes. Diabetes Res Clin Practice. 2002;58:87-96.
48. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003;26:2983-2989.
49. Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA. 2003;290:81-85.
50. Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the UK primary care setting. Diabetes Care. 2005;28:20-26.
51. Tanaka M, Endo K, Suzuki T, et al. Treatment for tseroid-induced diabetes with á-glucosidase inhibitor, voglibose. Eur J Neurol. 1998;5:315.
52. Carroll MF, Izard A, Riboni K, et al. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. Diabetes Care. 2002;25:2147-2152.
53. Hollingdal M, Sturis J, Gall MA, et al. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in type 2 diabetes. Diabet Med. 2005;22:1408-1413.
54. Vasquez-Carrera M, Silvestre JS. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol. 2004;26:445-461.
55. Perriello G, Pampanelli S, Porcellati F, et al. Insulin aspart improves meal time glycaemic control in patients with type 2 diabetes: a randomized, stratified, double blind and cross-over trial. Diabet Med. 2005;22:606-611.
56. Edelman SV, Morello CM. Strategies for insulin therapy in type 2 diabetes. South Med J. 2005;98:363-371.